Inflection Biosciences Selected as Tech Tour Contest Finalist for 2019

(26 Nov 2019)

Dublin, Ireland, November 26, 2019 – Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of cancer, today announced that Inflection Biosciences was selected as a finalist to present at the 13th Tech Tour Contest Final 2019 taking place on 9-10 December 2019 in Essen, Germany.

The Final will present 175+ European innovative companies in the high-technology sectors to an international audience of investors, key corporates and innovation experts.

About the Tech Tour Contest Final:

  • 150+ investors and corporates
  • 175+ presenting companies
  • 18 presentation sessions sector focused
  • 3 Award Winners
  • 350+ attendees
  • 14.3 € bln value of strategic deals of Tech Tour presenting companies over the last 7 years
  • Over 10 M assets under management in total of participating funds

About Inflection Biosciences

Inflection Biosciences Ltd, based in Dublin, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises the first-in-class AUM300 series (PIM/PI3K/mTOR inhibitors) partnered with AUM Biosciences, internal programs IBL-202 (PIM/PI3K inhibitor) and the IBL-100 series (selective pan-PIM kinase inhibitors), currently in pre-clinical stages of development. Data generated to date suggests potential application in a range of treatment resistant solid tumours and haematological malignancies. Inflection Biosciences was named ‘Start-up Company of the Year’ at the 2014 Irish Pharma Awards. For more information please visit www.inflectionbio.com

Image

Search

Search - Use spaces to separate your keywords
Inflection Biosciences. Suite 15, Anglesea House Carysfort Avenue, Blackrock,  Co. Dublin.  

 Company registration no. 509046.

© 2019 Inflection Biosciences.   Web Design by Webtrade